Últimas noticias sobre Algorhythm Holdings (NASDAQ:RIME) Bolsa

Algorhythm Holdings

Algorhythm Holdings Inc is an AI technology and consumer electronics holding company with two primary business units - SemiCab and Singing Machine. SemiCab is an artificial intelligence (AI) enabled software logistics business operated through its subsidiary, SemiCab Holdings, LLC. Singing Machine is a home karaoke consumer products business that designs and distributes karaoke products globally to retailers and eCommerce partners through its subsidiary, The Singing Machine Company, Inc. It generates the majority of its revenue from the Singing Machine business segment.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

TSMC y otras acciones destacaron en el premercado tras reportar ganancias récord. Descubre los mayores ganadores y perdedores.

Acciones de Taiwan Semiconductor (TSM) suben alrededor del 5%; 20 acciones en movimiento en el premercado de EE.UU.

APLD

AZTR

CRKN

CVGW

GLAC

HSDT

LFWD

MASS

ORKA

QBTS

SGBX

VMAR

VRME

Descubre las acciones ganadoras y perdedoras en el premercado, con Vision Marine liderando un aumento del 45%.

Las acciones de Vision Marine (VMAR) se disparan un 45%; 20 acciones que se están moviendo en premercado

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

Algorhythm Holdings Inc

BMO Capital analyst Ameet Thakkar maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $381 to $522.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on GE Vernova, Raises Price Target to $522

BMO Capital analyst Thomas Martin maintains BRP (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DOO#TSX">DOO</a>) with a Outperform and raises the price target from C$70 to C$75.

TSX:DOO

BMO Capital Maintains Outperform on BRP, Raises Price Target to C$75

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) posted better-than-expected earnings for the first quarter on Thursday.
Marvell reported quarterly adjusted earnings of 62 cents per share, which beat the Street estimate of 61 cents. Quarterly revenue came in at $1.9 billion, which beat the consensus estimate of $1.88 billion.
"Marvell delivered record revenue in the first quarter of $1.895 billion, a 63% year-over-year increase, and we are forecasting continued strong growth into the second quarter," said Matt Murphy, Marvell's CEO. "This momentum is being fueled by strong AI demand in the data center end market, where our revenue is benefiting from the rapid scaling of our custom silicon programs and robust shipments of our electro-optics products."
Marvell sees second-quarter net revenue of $2 billion, plus or minus 5%, and non-GAAP EPS of 67 cents, plus or minus five cents.
Marvell shares fell 6.9% to trade at $59.34 on Friday.
These analysts made changes to their price targets on Marvell following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Quinn Bolton maintained Marvell Tech with a Buy and lowered the price target from $100 to $85.</li>
<li>Wells Fargo analyst Aaron Rakers maintained the stock with an Overweight rating and lowered the price target from $120 to $95.</li>
<li>Keybanc analyst John Vinh maintained the stock with an Overweight rating and lowered the price target from $115 to $90.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated Marvell Tech with an Overweight rating and lowered the price target from $95 to $85.</li>
<li>Evercore ISI Group analyst Mark Lipacis maintained the stock with an Outperform rating and lowered the price target from $135 to $133.</li>
<li>Raymond James analyst Srini Pajjuri reiterated the stock with an Outperform rating and lowered the price target from $110 to $90.</li>
</ul>
Considering buying MRVL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MRVL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-1024x587.png" alt="" class="wp-image-933573" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30131758/image-420.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Earnings

MRVL

Marvell Technology Analysts Slash Their Forecasts After Q1 Earnings

BMO Capital analyst Sohrab Movahedi maintains Canadian Imperial Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) with a Outperform and raises the price target from $98 to $102.

BMO Capital Maintains Outperform on Canadian Imperial Bank, Raises Price Target to $102

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low disease activity levels for up to two years.
The latest <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-05-30" rel="noreferrer noopener">results</a> for this investigational Bruton&#8217;s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Ninety-nine patients entered the OLE and 93 remained in the OLE after 96 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45393806/ten-year-data-from-roches-breast-cancer-trial-shows-perjeta-based-regimen-cuts-death-risk-by-17" rel="noreferrer noopener">Ten-Year Data From Roche&#8217;s Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%</a>
During the OLE period, patients treated with fenebrutinib for up to 96 weeks had a low annualised relapse rate (ARR) of 0.06, and during this time there was no disability progression, as measured by the Expanded Disability Status Scale (EDSS).
MRI scans showed that fenebrutinib treatment suppressed disease activity in the brain. At 96 weeks zero new T1 gadolinium-enhancing (T1-Gd+) lesions, which are markers of active inflammation, were detected.
In the treatment group that switched from placebo to fenebrutinib in the OLE, the annualized rate of new or enlarging T2 lesions, which represent chronic disease burden, decreased from 6.72 at the end of the 12-week double-blind period to 0.34 by 96 weeks.
The safety profile of fenebrutinib in the OLE was consistent with previously reported data, with no new safety concerns identified at 96 weeks.
During the OLE, one patient experienced asymptomatic alanine aminotransferase elevation at OLE week 4, after 16 weeks on treatment, which resolved with treatment discontinuation.
Three Phase 3 trials are ongoing, including the FENhance 1 and 2 trials in RMS and the FENtrepid trial in primary progressive multiple sclerosis (PPMS). The first data from these studies are expected at the end of 2025.
In April, Roche announced it would invest $50 billion in the U.S. over&nbsp;the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" rel="noreferrer noopener">next five years</a>.
These investments further strengthen Roche&#8217;s already significant U.S. footprint, which includes 13 manufacturing and 15 R&amp;D sites across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to&nbsp;<a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-04-22?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">create</a> over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.
Price Action: RHHBY stock is trading higher by 1.83% to $40.25 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" target="_blank" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a></li>
</ul>
Photo by OleksSH via Shutterstock

Health Care

RHHBY

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

<a href="https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae" title="https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae">https://www.bloomberg.com/news/articles/2025-05-30/tsmc-is-said-to-evaluate-building-advanced-chip-plant-in-the-uae</a>

Global

'TSMC Is Said To Weigh Building Advanced Chip Plant In The UAE' - Bloomberg News

Raymond James analyst Olivia Tong reiterates Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and raises the price target from $450 to $500.

Reiteration

ULTA

Raymond James Reiterates Outperform on Ulta Beauty, Raises Price Target to $500

Raymond James analyst Brent Penter reiterates Starz Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRZ#NASDAQ">STRZ</a>) with a Outperform and raises the price target from $19 to $22.

STRZ

Raymond James Reiterates Outperform on Starz Entertainment, Raises Price Target to $22

Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares have been volatile in recent sessions amid broader EV market turbulence, despite long-term optimism surrounding its upcoming R2 model. 
What To Know: The recent downturn across EV stocks follows the House passage of President Donald Trump's "Big Beautiful Bill," which <a href="https://www.benzinga.com/25/05/45586258/is-trumps-big-beautiful-bill-a-major-roadblock-for-elon-musks-tesla-and-other-evs">proposes eliminating</a> the $7,500 federal EV tax credit for high-volume automakers, among other policy rollbacks.
Despite this political uncertainty, analysts are <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45617151/ubs-maintains-neutral-rating-for-rivian-stock-sets-price-13-price-target">cautiously optimistic</a> about Rivian. UBS raised its price target from $12 to $13, maintaining a Neutral rating, citing the affordable R2 SUV, slated for 2026 with a ~$45,000 price tag, as a key growth driver. 
CEO RJ Scaringe this week <a href="https://www.benzinga.com/25/05/45642153/rivian-ceo-rj-scaringe-touts-45000-rivian-r2s-updated-rear-suspension-cant-wait-for-folks">showcased</a> the R2&#8217;s innovative multi-link rear suspension, emphasizing cost-efficient engineering and enhanced ride quality.
Rivian is also investing $120 million to expand its Illinois facility, potentially adding hundreds of jobs. A $5.8 billion collaboration with Volkswagen to build a budget EV further strengthens its strategic outlook. 
While tariff concerns have led Rivian to cut its 2025 delivery forecast, a strong first-quarter performance and growing investor confidence keep the stock on steadier footing.
Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45698481/galaxy-digital-glxy-shares-slide-5-following-upsized-public-offering-announcement">Galaxy Digital Shares Slide 5% Following Upsized Public Offering Announcement</a> Price Action: RIVN shares are trading lower by 2.6% to $14.62 Friday afternoon. The stock is lower by 5.8% over the trailing week.
<h2 class="wp-block-heading">How To Buy RIVN Stock</h2>
By now you're likely curious about how to participate in the market for Rivian Automotive &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Rivian Automotive, which is trading at $14.83 as of publishing time, $100 would buy you 6.74 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RIVN has a 52-week high of $18.86 and a 52-week low of $9.50.
Image: Shutterstock

RIVN

Rivian (RIVN) Stock Is Volatile: What's Going On?

Raymond James analyst Srini Pajjuri reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and lowers the price target from $110 to $90.

Raymond James Reiterates Outperform on Marvell Tech, Lowers Price Target to $90

<a href="https://www.bloomberg.com/news/articles/2025-05-30/rivian-eyes-new-debt-deal-as-expected-vehicle-deliveries-slump?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/rivian-eyes-new-debt-deal-as-expected-vehicle-deliveries-slump?srnd=homepage-americas&amp;embedded-checkout=true</a>

General

'Rivian Eyes New Debt Deal as Expected Vehicle Deliveries Slump'- Bloomberg

Raymond James analyst Simon Leopold maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Outperform and raises the price target from $144 to $150.

DELL

Raymond James Maintains Outperform on Dell Technologies, Raises Price Target to $150

Raymond James analyst John Freeman reiterates APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Outperform and raises the price target from $23 to $25.

Raymond James Reiterates Outperform on APA, Raises Price Target to $25

Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) stock is trading higher Friday after the company reported better-than-expected first-quarter financial results on Thursday after the market closed and raised its fiscal-<a href="https://www.benzinga.com//node/45680852">year 2025 guidance</a>.
What To Know: The company posted adjusted earnings per share of 84 cents, beating the consensus estimate of 75 cents. In addition, Zscaler, reported sales of $678.03 million, beating the consensus estimate of $666.86 million, and representing a 23% year-over-year climb.
The company ended the quarter with $3.0 billion in cash and cash equivalents, an increase of $595.9 million, compared to the same time period last year.
&#8220;We delivered outstanding&nbsp;Q3&nbsp;results as an increasing number of customers adopt our expanding Zero Trust Exchange platform. We enable customers to realize Zero Trust Everywhere while lowering operational cost and complexity,&#8221; said Jay Chaudhry, Chairman and CEO of Zscaler.&nbsp;
Zscaler announced that it appointed Kevin Rubin as CFO. Rubin is set to succeed Remo Canessa, who announced plans to retire last year.
Outlook: The company sees fourth-quarter sales of $705 million to $707 million, versus the consensus estimate of $707.61 million. For fiscal-year 2025, Gap now sees adjusted earnings per share from $3.18 to $3.19, versus the consensus estimate of $3.07.
The company previously anticipated adjusted earnings per share from $3.04 to $3.09. Gap now expects sales of $2.66 billion, versus the consensus estimate of $2.65 billion. It previously saw sales from $2.64 billion to $2.65 billion.
Analyst Changes: Following the earnings report, multiple analysts announced price target adjustments.
<ul class="wp-block-list">
<li>JMP Securities analyst Trevor Walsh maintained a Market Outperform rating and raised the price target from $240 to $310.</li>
<li>Keybanc analyst Eric Heath maintained an Overweight rating and raised the price target from $290 to $310.</li>
<li>UBS analyst Roger Boyd maintained a Buy rating and raised the price target from $260 to $315.</li>
<li>Wells Fargo analyst Andrew Nowinski maintained an Equal-Weight rating and raised the price target from $210 to $260.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45695903/ulta-stock-is-rising-friday-whats-going-on">Ulta Stock Is Rising Friday: What&#8217;s Going On?</a>
ZS Price Action: At the time of publication, Zscaler stock is trading 8.53% higher at $272.63, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjTpP_ircuNAxVCpIkEHV7jF6UQFnoECAsQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Image: via Shutterstock

Zscaler Stock Is Gaining Friday: What's Going On?

Evercore ISI Group analyst Peter Levine maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $245 to $290.

Evercore ISI Group Maintains Outperform on Zscaler, Raises Price Target to $290

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) posted better-than-expected earnings for the <a href="https://www.benzinga.com/quote/BURL/earnings">first quarter on Thursday</a>.
The company reported first-quarter adjusted earnings per share of $1.60, beating the analyst consensus estimate of $1.41. Quarterly sales of $2.50 billion missed the Street view of $2.52 billion.
"We anticipate that tariffs will put significant pressure on our merchandise margin, but we are confident that, as long as tariffs do not increase from current levels, we can offset this pressure elsewhere in the P&amp;L," said the company's CEO Michael O'Sullivan.
Burlington Stores sees second-quarter adjusted EPS of $1.20-$1.30 versus the $1.34 estimate. The firm expects total sales to increase in the range of 5% to 7%; this assumes comparable store sales will increase in the range of 0% to 2%.
For FY25, the firm expects total sales to increase in the range of 6% to 8% on top of the 11% increase during Fiscal 2024.
Burlington shares fell 0.7% to trade at $226.17 on Friday.
These analysts made changes to their price targets on Burlington following earnings announcement.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Dana Telsey maintained Burlington Stores with an Outperform rating and lowered the price target from $340 to $300.</li>
<li>Barclays analyst Adrienne Yih maintained the stock with an Overweight rating and raised the price target from $254 to $299.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained Burlington Stores with an Outperform rating and lowered the price target from $345 to $310.</li>
</ul>
Considering buying BURL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/BURL/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-1024x535.png" alt="" class="wp-image-933555" style="width:683px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30130608/image-419.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

BURL

These Analysts Revise Their Forecasts On Burlington Stores After Q1 Results

Evercore ISI Group analyst Michael Binetti maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and raises the price target from $465 to $490.

Evercore ISI Group Maintains Outperform on Ulta Beauty, Raises Price Target to $490

<h3>Gainers</h3>
<ul>
<li>Global Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GITS#NASDAQ">GITS</a>) shares moved upwards by 108.4% to $1.98 during Friday's regular session. The market value of their outstanding shares is at $5.2 million. </li>
<li>Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) shares moved upwards by 35.28% to $0.21. The market value of their outstanding shares is at $5.1 million. </li>
<li>Starz Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRZ#NASDAQ">STRZ</a>) shares moved upwards by 19.24% to $19.69. The market value of their outstanding shares is at $328.9 million. </li>
<li>Mega Matrix (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MPU#AMEX">MPU</a>) stock rose 11.25% to $0.97. The market value of their outstanding shares is at $39.4 million. </li>
<li>Able View Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) stock rose 9.73% to $1.24. The company's market cap stands at $61.2 million. </li>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) shares increased by 9.28% to $1.53. The company's market cap stands at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares fell 19.6% to $4.72 during Friday's regular session. The company's market cap stands at $72.2 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) stock fell 17.75% to $0.7. The market value of their outstanding shares is at $10.0 million. </li>
<li>Newsmax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) shares decreased by 17.05% to $18.52. The market value of their outstanding shares is at $2.3 billion. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) stock fell 16.16% to $1.09. The market value of their outstanding shares is at $18.7 million. </li>
<li>Arena Group Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AREN#AMEX">AREN</a>) stock fell 15.73% to $4.02. The company's market cap stands at $191.1 million. </li>
<li>Phoenix New Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FENG#NYSE">FENG</a>) stock declined by 11.77% to $2.1. The company's market cap stands at $25.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABLV

ANTE

AREN

FENG

GITS

MCTR

NMAX

QMMM

12 Communication Services Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 171.6% to $2.83 during Friday's regular session. The market value of their outstanding shares is at $53.0 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock moved upwards by 50.92% to $5.72. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 39.78% to $2.78. The company's market cap stands at $48.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.48% to $915.0. The company's market cap stands at $11.9 billion. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares rose 23.0% to $2.62. The company's market cap stands at $146.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 20.47% to $1.74. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock fell 29.5% to $3.2 during Friday's regular session. The market value of their outstanding shares is at $36.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined by 29.48% to $18.48. The market value of their outstanding shares is at $13.7 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock fell 28.41% to $3.9. The market value of their outstanding shares is at $2.8 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 27.38% to $0.49. The market value of their outstanding shares is at $21.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 24.29% to $0.46. The market value of their outstanding shares is at $22.5 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares decreased by 21.01% to $10.98. The company's market cap stands at $91.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

ASBP

BMGL

CLGN

EXOZ

HBIO

IMNN

SMMT

SPRO

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock increased by 93.0% to $0.39 during Friday's regular session. The company's market cap stands at $20.4 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares moved upwards by 64.63% to $1.35. The market value of their outstanding shares is at $16.3 million. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares increased by 34.0% to $1.03. The market value of their outstanding shares is at $33.6 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock moved upwards by 26.8% to $0.31. The company's market cap stands at $71.0 million. </li>
<li>Li Bang International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBGJ#NASDAQ">LBGJ</a>) shares rose 18.05% to $1.7. The company's market cap stands at $31.8 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock increased by 16.93% to $5.73. The company's market cap stands at $12.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares fell 22.2% to $6.4 during Friday's regular session. The market value of their outstanding shares is at $215.9 million. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock decreased by 19.63% to $1.15. The market value of their outstanding shares is at $57.5 million. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares decreased by 19.1% to $10.51. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock decreased by 13.71% to $2.96. The market value of their outstanding shares is at $41.5 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares declined by 13.5% to $1.09. The company's market cap stands at $7.7 million. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock decreased by 12.54% to $2.9. The market value of their outstanding shares is at $63.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BURU

BWNB

CAPT

ELPW

GPUS

HCAI

LBGJ

LNZA

WETO

12 Industrials Stocks Moving In Friday's Intraday Session

Press Releases

Company Clears All Outstanding Cashless Warrants from December Capital Raise

Algorhythm Holdings Appoints Alex Andre as Chief Financial Officer

Algorhythm Holdings to Participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025 on March 25-26, 2025

Algorhythm Holdings to Present at the LD Micro Invitational XV Conference

Algorhythm Holdings Announces 2024 Financial Results

Algorhythm Holdings Acquires SemiCab India, Expands Global AI Transportation Footprint

Algorhythm Holdings Announces Major Fleet Expansion for SemiCab India

Algorhythm Holdings to Announce its Financial Results for the First Quarter 2025

Comments

Algorhythm Holdings

Noticias

Últimas noticias sobre Algorhythm Holdings (NASDAQ:RIME) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL